拉米夫定治疗慢性乙型肝炎的疗效研究

目的：研究抗－HBV药拉米夫定治疗慢性乙型肝炎的抗乙型肝炎病毒DNA的疗效。方法：分治疗组和对照组，治疗组每日1次口服拉米夫定100mg，疗程一年；对照组用一般护肝药治疗。定期检测血常规、肝功能及病毒学指标等。结果：拉米夫定治疗慢性乙型肝炎疗程一年，ALT复常率为90．7％，HBV DNA阴转率为73．1％，与对照组相比差异有显著性（P＜0．05），HBeAg阴转率为50．0％，HBeAg／抗－HBe的血清转换率为38．2％，与对照组相比差异无显著性（P＞0．05），病情反复，ALT再次升高者治疗组为3．1％，与对照组相比较差异有显著性（P＜0．05），治疗2例重症肝炎患者，无1例死亡。结论：拉米夫定能有效地抑制HBV DNA的复制，使ALT恢复正常，降低慢性乙型肝炎的复发率，提高患者存活率。

Observation on the therapeutic effect of Lamivudin on chronic hepatitis B

Objective To observe the therapeutic effect of Lamivudine on controlling hepatitis B virus DNA replication. Methods The liver disease patients were divided into two groups,the treated group ( n =64) was given Lamivudine 100 mg once a day for one year and was additionally given liver protection drugs according to their liver function,while the control group ( n =30) was given common liver protection drugs.The blood routine test,liver function and the viral markers were detected at defined times.Results The results showed that after one year treatment of chronic hepatitis B with Lamivudine,the recovery rate of ALT was 90.7%,the negative conversion rate of HBV DNA was 73.1% showing a significant difference as compared with the control group ( P <0.05).The negative seroconversion rate of HBeAg was 50%,HBeAg/anti HBe changing rate was 38.2%,that had no significant different as compared with the control group ( P <0.05).The percentage for disease relapse and second elevation of ALT was 3.1% in therapeutic group that was significantly different from that of the control group ( P <0.05).Two cases with severe hepatitis in the treated group were all alive.Conclusion Lamivudine could effectively control HBV DNA replication,making ALT normal,it also could decrease the relapse rate of chronic hepatitis B and raise the survival rate of the patients with liver disease.